Production (Stage)
NLS Pharmaceutics AG
NLSP
$2.30
$0.2210.58%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 716.00K | 716.00K | 891.10K | 891.10K | 1.37M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 791.40K | 791.40K | 1.03M | 1.03M | 2.13M |
| Operating Income | -791.40K | -791.40K | -1.03M | -1.03M | -2.13M |
| Income Before Tax | 27.50K | 27.50K | -1.02M | -1.02M | -2.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 27.50K | 27.50K | -1.02M | -1.02M | -2.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27.50K | 27.50K | -1.02M | -1.02M | -2.28M |
| EBIT | -791.40K | -791.40K | -1.03M | -1.03M | -2.13M |
| EBITDA | -790.60K | -789.90K | -1.02M | -1.02M | -2.13M |
| EPS Basic | -0.50 | -0.50 | -0.97 | -0.97 | -2.39 |
| Normalized Basic EPS | -0.26 | -0.26 | -0.61 | -0.61 | -1.49 |
| EPS Diluted | -0.50 | -0.50 | -0.97 | -0.97 | -2.39 |
| Normalized Diluted EPS | -0.26 | -0.26 | -0.61 | -0.61 | -1.49 |
| Average Basic Shares Outstanding | 2.04M | 2.04M | 1.05M | 1.05M | 954.40K |
| Average Diluted Shares Outstanding | 2.04M | 2.04M | 1.05M | 1.05M | 954.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |